Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
B lymphocyte antigen CD19 (CD19)
- Target
- CD19
- Molecular classification
- Type I transmembrane glycoprotein, Immunoglobulin superfamily (IgSF), Receptor
01
Overview
CD19 is a 95 kDa type I transmembrane glycoprotein expressed exclusively on B cells from early pro-B cell stage through mature B cells, but is generally lost upon differentiation into plasma cells, with some conflicting recent findings. It functions as a crucial co-receptor with the B-cell antigen receptor (BCR), modulating signaling thresholds and enhancing responses to antigens. It is a validated therapeutic target in B-cell malignancies.
- Other names
- CD19 moleculeCluster of Differentiation 19B-Lymphocyte Surface Antigen B4T-Cell Surface Antigen Leu-12CVID3
02
Mechanism of action
Monoclonal antibody therapies bind to CD19, inducing cell death through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct apoptosis. CAR-T cell therapies genetically modify T cells to express a receptor targeting CD19, leading to targeted killing of CD19-expressing cells.
03
Biological functions
Signal transductionImmune responseB-cell activationAntibody productionAntigen presentationCell proliferationB cell differentiation
04
Disease associations
LeukemiaLymphomaAutoimmune diseasesImmunodeficiencyCancer
05
Safety considerations
Cytokine release syndrome (CRS) with CAR-T cell therapyOn-target, off-tumor toxicity with CAR-T cell therapyB-cell aplasiaHypogammaglobulinemia
06
Interacting drugs
Anti-CD19 monoclonal antibodies
2 more in the full profile.
07
Biomarkers
CD19 expression level for diagnosis and prognosis in B-cell malignanciesCD19 expression for patient selection for CAR-T cell therapy
Beyond the preview
Go deeper on B lymphocyte antigen CD19 (CD19).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B lymphocyte antigen CD19 (CD19).